A systematic review and meta-analysis on efficacy and safety of Ganaxolone in epilepsy
- PMID: 38606458
- DOI: 10.1080/14656566.2024.2342413
A systematic review and meta-analysis on efficacy and safety of Ganaxolone in epilepsy
Abstract
Introduction: Ganaxolone has exhibited potential in managing seizures for epilepsy. This systematic review and meta-analysis aim to assess both the safety and efficacy of Ganaxolone for refractory epilepsy.
Methods: A thorough search of electronic databases was conducted to identify relevant randomized controlled trials involving patients with drug-resistant focal epilepsy and CDKL5 deficiency disorder. Efficacy and safety outcomes were extracted from the selected studies. Cochrane Review Manager was utilized for data synthesis and analysis, with risk ratios and mean differences calculated to evaluate the efficacy and safety profile of Ganaxolone.
Results: The meta-analysis included a total of five randomized controlled trials. Ganaxolone exhibited significant efficacy in reducing seizure frequency by at least 50% from baseline [RR 0.90 (95% CI: 0.83, 0.98), p = 0.02]. However, the results did not reach significance for reducing 28-day seizure frequency [Mean Difference -1.45 (95% CI: -3.39, 0.49), p = 0.14]. Ganaxolone exhibited a positive safety profile, with no statistically significant occurrence of adverse events [RR 1.30 (95% CI: 0.93, 1.83), p = 0.12] and adverse events leading to discontinuation of the study drug [RR 1.01 (95% CI: 0.42, 2.39), p = 0.99] compared to placebo.
Conclusion: Ganaxolone presents itself as a viable therapeutic option for refractory epilepsy, showing efficacy in reducing seizure frequency and exhibited a favorable safety profile.
Prospero registration number: CRD42023434883.
Keywords: CDKL5 deficiency disorder; Ganaxolone; epilepsy; neurosteroid; seizure.
Similar articles
-
The efficacy and safety of ganaxolone for the treatment of refractory epilepsy: A meta-analysis from randomized controlled trials.Epilepsia Open. 2023 Mar;8(1):90-99. doi: 10.1002/epi4.12669. Epub 2022 Nov 15. Epilepsia Open. 2023. PMID: 36333279 Free PMC article.
-
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.Lancet Neurol. 2022 May;21(5):417-427. doi: 10.1016/S1474-4422(22)00077-1. Lancet Neurol. 2022. PMID: 35429480 Clinical Trial.
-
Brivaracetam add-on therapy for drug-resistant epilepsy.Cochrane Database Syst Rev. 2022 Mar 14;3(3):CD011501. doi: 10.1002/14651858.CD011501.pub3. Cochrane Database Syst Rev. 2022. PMID: 35285519 Free PMC article. Review.
-
Rufinamide add-on therapy for refractory epilepsy.Cochrane Database Syst Rev. 2018 Apr 25;4(4):CD011772. doi: 10.1002/14651858.CD011772.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2020 Nov 8;11:CD011772. doi: 10.1002/14651858.CD011772.pub3. PMID: 29691835 Free PMC article. Updated. Review.
-
Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures.Epilepsia. 2017 Apr;58(4):558-564. doi: 10.1111/epi.13705. Epub 2017 Feb 23. Epilepsia. 2017. PMID: 28230252 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
